In all seriousness, the product/s are available in 8 regions...

In all seriousness, the product/s are available in 8 regions across the globe. The Viradx product has basically replaced the Covidx product which at its peak was pulling in $1.7Million a year. Those product/s have been in market for 3-4 years now.

The total CY sales for all their products is $1.5Million to date which works out to be at best case scenario, 111 boxes per distributor. However, we also know that isn't the case as they all of a sudden decided to declare BINX revenue also:




We are talking globally. So CLIA waiver is irrelevant to the majority of the revenue anyway.

We have also not received any update on the reimbursements as you said, however Paul indicated in the August (August 2) webinar that in January 2024 they received the PLA code for reimbursements. They then had to pitch a deck for the rate which was in May. He then said that it went straight through to decisioning team and they were expecting the confirmed amount in about 4-5 weeks from the date of the webinar. They would mean they are either already overdue for that decision or they have failed to come to a reimbursement rate and are now mucking about with administration. The rate wont be published until next year but they can advertise it to clients. Why not release an update on this to the market?

Further, they said there was an immediate impact in the Uni health sector for Febridx. "Very large market" which translates to bugger all difference in 12 months worth of sales.

Febridx which will be their long term mainstream product really needs to be pulling in 10's of millions of dollars per quarter to warrant a substantial re rate on the share price.

You can now see that given the dump of 4Million+ shares into the .4c share line and we are on a sharp trajectory back to CR price.